small nuclear ribonucleoprotein polypeptide C pseudogene 4Genealiases: []
Q-omics provides the consensus-scored SNRPCP4 profile across patient tissues and cancer cell-line models. SNRPCP4 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNRPCP4 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, SNRPCP4 RNA expression shows 8,195 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, THCA, and ESCA as cancer lineages where SNRPCP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNRPCP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNRPCP4 survival associations across molecular data types. SNRPCP4 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNRPCP4 RNA expression–survival associations across cancer types. High SNRPCP4 expression shows unfavorable associations in KIRC, COAD, UVM, BRCA and MESO, but favorable associations in LAML. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SNRPCP4 RNA expression.
This table summarizes SNRPCP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNRPCP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNRPCP4 shows lower tumor expression in THCA and LUSC and higher tumor expression in HNSC. The THCA box plot shows higher SNRPCP4 RNA expression in normal versus tumor tissue (log2 FC = −0.037, t-test p = .007).
This table shows molecular features associated with SNRPCP4 in patient tissues and cancer cell lines. In patient samples, SNRPCP4 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
